|The full issue is available to subscribers||Subscriber Login|
Antiviral drugs can be used for prophylaxis and treatment of influenza. Frequently updated information on influenza activity, testing for influenza, and antiviral resistance is available from the CDC at www.cdc.gov/flu.
INDICATIONS FOR TREATMENT — The CDC recommends starting antiviral treatment as soon as possible after illness onset, without waiting for the results of influenza testing. Antiviral treatment is indicated for all persons with suspected or confirmed influenza who are at high risk for complications, including children <2 years old, persons <19 years old receiving long-term aspirin therapy, adults ≥65 years old, morbidly obese persons (BMI ≥40), women who are pregnant or ≤2 weeks postpartum, persons of American Indian/Alaska Native heritage, residents of nursing homes or other chronic care facilities, and persons who are immunosuppressed or... more
- CDC. Influenza antiviral medications: summary for clinicians. Available at: www.cdc.gov. Accessed December 20, 2016.
- Peramivir (Rapivab): an IV neuraminidase inhibitor for treatment of influenza. Med Lett Drugs Ther 2015; 57:17.
- AE Fiore et al. Antiviral agents for the treatment and chemoprophylaxis of influenza – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.
- J Dobson et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015; 385:1729.
- IDSA. Statement by the Infectious Disease Society of America (IDSA) on the recent publication on "Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children." April 2014. Available at: www.idsociety.org. Accessed December 20, 2016.
- In brief: Concerns about oseltamivir (Tamiflu). Med Lett Drugs Ther 2015; 57:14.
- JK Louie et al. Neuraminidase inhibitors for critically ill children with influenza. Pediatrics 2013; 132:e1539.
- SG Muthuri et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2:395.
- JK Louie et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55:1198.
- MH Yudin. Risk management of seasonal influenza during pregnancy: current perspectives. Int J Womens Health 2014; 6:681.
- IK Oboho et al. Benefit of early initiation of influenza antiviral treatment to pregnant women hospitalized with laboratory-confirmed influenza. J Infect Dis 2016; 214:507.
- LM Ghulmiyyah et al. Influenza and its treatment during pregnancy: a review. J Neonatal Perinatal Med 2015; 8:297.
- CDC. Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. Available at: www.cdc.gov. Accessed December 20, 2016.
- AC Hurt et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015. Antiviral Res 2016; 132:178.
- QM Le et al. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 2010; 362:86.
- C Renaud et al. H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerg Infect Dis 2011; 17:653.
- E Takashita et al. Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016. Euro Surveill 2016; 21(24): Article 2.
- S Toovey et al. Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review. Adv Ther 2012; 29:826.
- Influenza vaccine for 2016-2017. Med Lett Drugs Ther 2016; 58:127.